10 Best Performing Healthcare Stocks So Far in 2025

8. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

YTD Performance: 55.01%

Number of Hedge Fund Holders: 38

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system (CNS) conditions with limited treatment options. Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy or obstructive sleep apnea.

Apart from Auvelity and Sunosi, the company’s pipeline features five innovative late-stage product candidates in development, along with nine indications across psychiatry and neurology. Axsome Therapeutics, Inc.’s (NASDAQ:AXSM) late-stage pipeline positions it to deliver new medicines across therapeutic areas, impacting over 150 million patients in the US. If developed successfully, this portfolio holds the potential to provide more than $16 billion in peak sales.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) also has strong financials. It reported quarterly product revenue of over $100 million for the first time in fiscal Q3 2024. This quarterly performance translates to an annual revenue rate of around $420 million. The company reported these results just three quarters into its second full year as a commercial therapy.